{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T08:19:13Z","timestamp":1763367553906,"version":"3.37.3"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2022,7,2]],"date-time":"2022-07-02T00:00:00Z","timestamp":1656720000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,7,2]],"date-time":"2022-07-02T00:00:00Z","timestamp":1656720000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Turkish Rheumatology Society"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"DOI":"10.1007\/s00296-022-05164-7","type":"journal-article","created":{"date-parts":[[2022,7,2]],"date-time":"2022-07-02T07:05:53Z","timestamp":1656745553000},"page":"1741-1750","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Higher antibody responses after mRNA-based vaccine compared to inactivated vaccine against SARS-CoV-2 in Behcet\u2019s syndrome"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6531-8138","authenticated-orcid":false,"given":"Ayse","family":"Ozdede","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8111-8072","authenticated-orcid":false,"given":"Okan Kadir","family":"Nohut","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2959-0978","authenticated-orcid":false,"given":"Zeynep","family":"Atli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4970-9216","authenticated-orcid":false,"given":"Ye\u015fim Tuyji","family":"Tok","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9582-8374","authenticated-orcid":false,"given":"Sabriye","family":"Guner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5133-4532","authenticated-orcid":false,"given":"Erkan","family":"Yilmaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3469-7307","authenticated-orcid":false,"given":"Didar","family":"Ucar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2866-4004","authenticated-orcid":false,"given":"Ugur","family":"Uygunoglu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6625-1652","authenticated-orcid":false,"given":"Vedat","family":"Hamuryudan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4965-2918","authenticated-orcid":false,"given":"Emire","family":"Seyahi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,7,2]]},"reference":[{"key":"5164_CR1","unstructured":"https:\/\/covid19.who.int\/. Accessed 6 June 2022"},{"key":"5164_CR2","doi-asserted-by":"publisher","unstructured":"Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA, Rouphael N, Creech CB, McGettigan J, Khetan S, Segall N, Solis J, Brosz A, Fierro C, Schwartz H, Neuzil K, Corey L, Gilbert P, Janes H, Follmann D, Marovich M, Mascola J, Polakowski L, Ledgerwood J, Graham BS, Bennett H, Pajon R, Knightly C, Leav B, Deng W, Zhou H, Han S, Ivarsson M, Miller J, Zaks T, COVE Study Group (2021) Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med 384(5):403\u2013416. https:\/\/doi.org\/10.1056\/NEJMoa2035389(PMID: 33378609; PMCID: PMC7787219)","DOI":"10.1056\/NEJMoa2035389"},{"issue":"10296","key":"5164_CR3","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/S0140-6736(21)01429-X","volume":"398","author":"MD Tanriover","year":"2021","unstructured":"Tanriover MD, Do\u011fanay HL, Akova M, G\u00fcner HR, Azap A, Akhan S, K\u00f6se \u015e, Erdin\u00e7 F\u015e, Akal\u0131n EH, Tabak \u00d6F, Pulluk\u00e7uH B\u00d6, \u015eim\u015fek Yavuz S, Turhan \u00d6, Y\u0131ld\u0131rmak MT, K\u00f6ksal\u0130 TY, Korten V, Y\u0131lmaz G, \u00c7elen MK, Alt\u0131n S, \u00c7elik \u0130, Bay\u0131nd\u0131r Y, Karao\u011flan \u0130, Y\u0131lmaz A, \u00d6zkul A, G\u00fcr H, Unal S (2021) Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. Lancet 398(10296):213\u2013222. https:\/\/doi.org\/10.1016\/S0140-6736(21)01429-X ((PMID: 34246358; PMCID: PMC8266301))","journal-title":"Lancet"},{"key":"5164_CR4","doi-asserted-by":"publisher","first-page":"577765","DOI":"10.1016\/j.jneuroim.2021.577765","volume":"362","author":"II Ismail","year":"2022","unstructured":"Ismail II, Salama S (2022) A systematic review of cases of CNS demyelination following COVID-19 vaccination. J Neuroimmunol 362:577765. https:\/\/doi.org\/10.1016\/j.jneuroim.2021.577765 (Epub 2021 Nov 9. PMID: 34839149; PMCID: PMC8577051)","journal-title":"J Neuroimmunol"},{"issue":"11","key":"5164_CR5","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1097\/TP.0000000000003900","volume":"105","author":"BJ Boyarsky","year":"2021","unstructured":"Boyarsky BJ, Barbur I, Chiang TP, Ou MT, Greenberg RS, Teles AT, Krach MR, L\u00f3pez JI, Garonzik-Wang JM, Avery RK, Massie AB, Segev DL, Werbel WA (2021) SARS-CoV-2 messenger RNA vaccine immunogenicity in solid organ transplant recipients with prior COVID-19. Transplantation 105(11):270\u2013271. https:\/\/doi.org\/10.1097\/TP.0000000000003900 (PMID: 34284420; PMCID: PMC8549119)","journal-title":"Transplantation"},{"issue":"9","key":"5164_CR6","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1002\/acr2.11299","volume":"3","author":"C Ammitzb\u00f8ll","year":"2021","unstructured":"Ammitzb\u00f8ll C, Bartels LE, B\u00f8gh Andersen J, Risb\u00f8l Vils S, Elbaek Misteg\u00e5rd C, Dahl Johannsen A, From Hermansen ML, Kragh Thomsen M, Erikstrup C, Hauge EM, Troldborg A (2021) Impaired antibody response to the BNT162b2 messenger RNA coronavirus disease 2019 vaccine in patients with systemic lupus erythematosus and rheumatoid arthritis. ACR Open Rheumatol 3(9):622\u2013628. https:\/\/doi.org\/10.1002\/acr2.11299","journal-title":"ACR Open Rheumatol"},{"issue":"8","key":"5164_CR7","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1007\/s00296-021-04910-7","volume":"41","author":"E Seyahi","year":"2021","unstructured":"Seyahi E, Bakhdiyarli G, Oztas M, Kuskucu MA, Tok Y, Sut N, Ozcifci G, Ozcaglayan A, Balkan II, Saltoglu N, Tabak F, Hamuryudan V (2021) Antibody response to inactivated COVID-19 vaccine (CoronaVac) in immune-mediated diseases: a controlled study among hospital workers and elderly. Rheumatol Int 41(8):1429\u20131440. https:\/\/doi.org\/10.1007\/s00296-021-04910-7","journal-title":"Rheumatol Int"},{"issue":"11","key":"5164_CR8","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1001\/jamaoncol.2021.4381","volume":"7","author":"TA Ollila","year":"2021","unstructured":"Ollila TA, Lu S, Masel R, Zayac A, Paiva K, Rogers RD, Olszewski AJ (2021) Antibody response to COVID-19 vaccination in adults with hematologic malignant disease. JAMA Oncol 7(11):1714\u20131716. https:\/\/doi.org\/10.1001\/jamaoncol.2021.4381 (PMID: 34379085; PMCID: PMC8358793)","journal-title":"JAMA Oncol"},{"key":"5164_CR9","unstructured":"Interim recommendations for an extended primary series with an additional vaccine dose for COVID-19 vaccination in immunocompromised persons. https:\/\/www.who.int\/publications\/i\/item\/WHO-2019-nCoV-vaccines-SAGE_recommendation-immunocompromised-persons. Accessed 29 Apr 2022"},{"issue":"4","key":"5164_CR10","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1038\/s41584-022-00755-x","volume":"18","author":"R Grainger","year":"2022","unstructured":"Grainger R, Kim AHJ, Conway R, Yazdany J, Robinson PC (2022) COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations. Nat Rev Rheumatol 18(4):191\u2013204. https:\/\/doi.org\/10.1038\/s41584-022-00755-x (Epub 2022 Feb 25. PMID: 35217850; PMCID: PMC8874732)","journal-title":"Nat Rev Rheumatol"},{"issue":"2","key":"5164_CR11","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/nrrheum.2017.208","volume":"14","author":"H Yazici","year":"2018","unstructured":"Yazici H, Seyahi E, Hatemi G, Yazici Y (2018) Beh\u00e7et syndrome: a contemporary view. Nat Rev Rheumatol 14(2):107\u2013119. https:\/\/doi.org\/10.1038\/nrrheum.2017.208 (Erratum in: Nat Rev Rheumatol. 2018 Jan 24; 14 (2): 119. PMID: 29296024)","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"5164_CR12","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1097\/00005792-200301000-00006","volume":"82","author":"E Kural-Seyahi","year":"2003","unstructured":"Kural-Seyahi E, Fresko I, Seyahi N, Ozyazgan Y, Mat C, Hamuryudan V, Yurdakul S, Yazici H (2003) The long-term mortality and morbidity of Beh\u00e7et syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine (Baltimore) 82(1):60\u201376. https:\/\/doi.org\/10.1097\/00005792-200301000-00006 (PMID: 12544711)","journal-title":"Medicine (Baltimore)"},{"issue":"5","key":"5164_CR13","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1007\/s11739-019-02046-y","volume":"14","author":"E Seyahi","year":"2019","unstructured":"Seyahi E (2019) Phenotypes in Beh\u00e7et\u2019s syndrome. Intern Emerg Med 14(5):677\u2013689. https:\/\/doi.org\/10.1007\/s11739-019-02046-y (PMID: 30747365)","journal-title":"Intern Emerg Med"},{"key":"5164_CR14","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-022-05119-y","author":"A Ozdede","year":"2022","unstructured":"Ozdede A, Guner S, Ozcifci G, Yurttas B, Toker Dincer Z, Atli Z, Uyguno\u011flu U, Durmaz E, U\u00e7ar D, U\u011furlu S, Saip S, Tabak F, Hamuryudan V, Seyahi E (2022) Safety of SARS-CoV-2 vaccination in patients with Behcet\u2019s syndrome and familial Mediterranean fever: a cross-sectional comparative study on the effects of M-RNA based and inactivated vaccine. Rheumatol Int. https:\/\/doi.org\/10.1007\/s00296-022-05119-y (PMID: 35376962; PMCID: PMC8977433)","journal-title":"Rheumatol Int"},{"issue":"4","key":"5164_CR15","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1007\/s40121-021-00504-9","volume":"10","author":"E Riester","year":"2021","unstructured":"Riester E, Majchrzak M, M\u00fchlbacher A, Tinguely C, Findeisen P, Hegel JK, Laimighofer M, Rank CM, Sch\u00f6nfeld K, Langen F, Laengin T, Niederhauser C (2021) Multicentre performance evaluation of the elecsys anti-SARS-CoV-2 immunoassay as an aid in determining previous exposure to SARS-CoV-2. Infect Dis Ther 10(4):2381\u20132397. https:\/\/doi.org\/10.1007\/s40121-021-00504-9","journal-title":"Infect Dis Ther"},{"issue":"4","key":"5164_CR16","doi-asserted-by":"publisher","first-page":"e03149","DOI":"10.1128\/JCM.03149-20","volume":"59","author":"V Higgins","year":"2021","unstructured":"Higgins V, Fabros A, Kulasingam V (2021) Quantitative measurement of anti-SARS-CoV-2 antibodies: analytical and clinical evaluation. J Clin Microbiol 59(4):e03149-e3220. https:\/\/doi.org\/10.1128\/JCM.03149-20","journal-title":"J Clin Microbiol"},{"key":"5164_CR17","doi-asserted-by":"publisher","DOI":"10.1101\/2021.10.04.21264521","volume":"12","author":"S Jochum","year":"2022","unstructured":"Jochum S, Kirste I, Hortsch S, Grunert VP, Legault H, Eichenlaub U, Kashlan B, Pajon R (2022) Clinical utility of elecsys anti-SARS-CoV-2 S assay in COVID-19 vaccination: an exploratory analysis of the mRNA-1273 phase 1 trial. Front Immunol 12:798117. https:\/\/doi.org\/10.1101\/2021.10.04.21264521","journal-title":"Front Immunol"},{"issue":"8","key":"5164_CR18","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1515\/cclm-2021-0313","volume":"59","author":"A Padoan","year":"2021","unstructured":"Padoan A, Bonfante F, Cosma C, Di Chiara C, Sciacovelli L, Pagliari M, Bortolami A, Costenaro P, Musso G, Basso D, Giaquinto C, Plebani M (2021) Analytical and clinical performances of a SARS-CoV-2 S-RBD IgG assay: comparison with neutralization titers. Clin Chem Lab Med 59(8):1444\u20131452. https:\/\/doi.org\/10.1515\/cclm-2021-0313","journal-title":"Clin Chem Lab Med"},{"issue":"6","key":"5164_CR19","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1136\/annrheumdis-2021-221922","volume":"81","author":"S Ahmed","year":"2022","unstructured":"Ahmed S, Mehta P, Paul A, Anu S, Cherian S, Shenoy V, Nalianda KK, Joseph S, Poulose A, Shenoy P (2022) Postvaccination antibody titres predict protection against COVID-19 in patients with autoimmune diseases: survival analysis in a prospective cohort. Ann Rheum Dis 81(6):868\u2013874. https:\/\/doi.org\/10.1136\/annrheumdis-2021-221922","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"5164_CR20","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1111\/resp.14191","volume":"27","author":"C Mok","year":"2022","unstructured":"Mok C, Cohen CA, Cheng SMS, Chen C, Kwok KO, Yiu K, Chan TO, Bull M, Ling KC, Dai Z, Ng SS, Lui GC, Wu C, Amarasinghe GK, Leung DW, Wong SYS, Valkenburg SA, Peiris M, Hui DS (2022) Comparison of the immunogenicity of BNT162b2 and CoronaVac COVID-19 vaccines in Hong Kong. Respirology 27(4):301\u2013310. https:\/\/doi.org\/10.1111\/resp.14191","journal-title":"Respirology"},{"issue":"1","key":"5164_CR21","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/S1473-3099(21)00479-5","volume":"22","author":"D Saur\u00e9","year":"2022","unstructured":"Saur\u00e9 D, O\u2019Ryan M, Torres JP, Zuniga M, Santelices E, Basso LJ (2022) Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study. Lancet Infect Dis 22(1):56\u201363. https:\/\/doi.org\/10.1016\/S1473-3099(21)00479-5","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"5164_CR22","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1002\/jmv.27620","volume":"94","author":"D \u00c7a\u011flayan","year":"2022","unstructured":"\u00c7a\u011flayan D, S\u00fcner AF, \u015eiyve N, G\u00fczel I, Irmak \u00c7, I\u015fik E, Appak \u00d6, \u00c7elik M, \u00d6zt\u00fcrk G, Alp \u00c7avu\u015f S, Erg\u00f6r G, Sayiner A, Erg\u00f6r A, Demiral Y, Kili\u00e7 B (2022) An analysis of antibody response following the second dose of CoronaVac and humoral response after booster dose with BNT162b2 or CoronaVac among healthcare workers in Turkey. J Med Virol 94(5):2212\u20132221. https:\/\/doi.org\/10.1002\/jmv.27620","journal-title":"J Med Virol"},{"issue":"4","key":"5164_CR23","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1002\/jmv.27531","volume":"94","author":"R Bag Soytas","year":"2022","unstructured":"Bag Soytas R, Cengiz M, Islamoglu MS, Borku Uysal B, Yavuzer S, Yavuzer H (2022) Antibody responses to COVID-19 vaccines in older adults. J Med Virol 94(4):1650\u20131654. https:\/\/doi.org\/10.1002\/jmv.27531","journal-title":"J Med Virol"},{"key":"5164_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/1759720X221089586","volume":"14","author":"H So","year":"2022","unstructured":"So H, Li T, Chan V, Tam LS, Chan PK (2022) Immunogenicity and safety of inactivated and mRNA COVID-19 vaccines in patients with systemic lupus erythematosus. Ther Adv Musculoskelet Dis 14:1\u20139. https:\/\/doi.org\/10.1177\/1759720X221089586","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"5164_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.103486","volume":"58","author":"S Ozakbas","year":"2022","unstructured":"Ozakbas S, Baba C, Dogan Y, Cevik S, Ozcelik S, Kaya E (2022) Comparison of SARS-CoV-2 antibody response after two doses of mRNA and inactivated vaccines in multiple sclerosis patients treated with disease-modifying therapies. Mult Scler Relat Disord 58:103486. https:\/\/doi.org\/10.1016\/j.msard.2022.103486","journal-title":"Mult Scler Relat Disord"},{"key":"5164_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.103690","volume":"59","author":"E Ciampi","year":"2022","unstructured":"Ciampi E, Uribe-San-Martin R, Soler B, Garc\u00eda L, Guzman J, Pelayo C, J\u00fcrgensen L, Guzman I, Vera F, Galleguillos L, C\u00e1rcamo C (2022) Safety and humoral response rate of inactivated and mRNA vaccines against SARS-CoV-2 in patients with multiple sclerosis. Multiple Sclerosis Relat Disord 59:103690. https:\/\/doi.org\/10.1016\/j.msard.2022.103690","journal-title":"Multiple Sclerosis Relat Disord"},{"issue":"12","key":"5164_CR27","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.6002\/ect.2021.0402","volume":"19","author":"\u00c7 Erol","year":"2021","unstructured":"Erol \u00c7, Yan\u0131k Yal\u00e7\u0131n T, Sar\u0131 N, Bayraktar N, Ayvazo\u011flu Soy E, Yavuz \u00c7olak M, Azap \u00d6, Arslan H, Haberal M (2021) Differences in antibody responses between an inactivated SARS-CoV-2 vaccine and the BNT162b2 mRNA vaccine in solid-organ transplant recipients. Exp Clin Transplant 19(12):1334\u20131340. https:\/\/doi.org\/10.6002\/ect.2021.0402","journal-title":"Exp Clin Transplant"},{"issue":"3","key":"5164_CR28","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1093\/ckj\/sfab291","volume":"15","author":"M Seija","year":"2021","unstructured":"Seija M, Rammauro F, Santiago J, Orihuela N, Zulberti C, Machado D, Recalde C, Noboa J, Frantchez V, Astesiano R, Yandi\u00e1n F, Guerisoli A, Morra \u00c1, Cassinelli D, Coelho C, de Aramburu B, Gonz\u00e1lez-Severgnini P, Moreno R, Pippolo A, L\u00f3pez G, Lemos M, Somariva L, L\u00f3pez E, Fumero S, Orihuela C, Rodr\u00edguez R, Acu\u00f1a G, Rabaza V, Perg N, Cordero R, Reisfeld C, Olivera P, Montero P, Nogueira C, Nalerio C, Orihuela S, Curi L, Burgstaller E, Noboa O, Pritsch O, Nin M, Bianchi S (2021) Comparison of antibody response to SARS-CoV-2 after two doses of inactivated virus and BNT162b2 mRNA vaccines in kidney transplant. Clin Kidney J 15(3):527\u2013533. https:\/\/doi.org\/10.1093\/ckj\/sfab291","journal-title":"Clin Kidney J"},{"key":"5164_CR29","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac167","author":"ME Balcells","year":"2022","unstructured":"Balcells ME, Le Corre N, Dur\u00e1n J, Ceballos ME, Vizcaya C, Mondaca S, Dib M, Rabagliati R, Sarmiento M, Burgos PI, Espinoza M, Ferr\u00e9s M, Martinez-Valdebenito C, Ruiz-Tagle C, Ortiz C, Ross P, Budnik S, Solari S, Vizcaya ML\u00c1, Lembach H, Berrios-Rojas R, Melo-Gonz\u00e1lez F, R\u00edos M, Kalergis AM, Bueno SM, Nervi B (2022) Reduced immune response to inactivated SARS-CoV-2 vaccine in a cohort of immunocompromised patients in Chile. Clin Infect Dis. https:\/\/doi.org\/10.1093\/cid\/ciac167","journal-title":"Clin Infect Dis"},{"key":"5164_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10067-022-06134-x","volume":"19","author":"SG Pasoto","year":"2022","unstructured":"Pasoto SG, Halpern ASR, Guedes LKN, Ribeiro ACM, Yuki ENF, Saad CGS, da Silva CAA, de vinci Kanda Kupa L, Villamar\u00edn LEB, de Oliveira Martins VA, Martins CCMF, Deveza GBH, Leon EP, Bueno C, Pedrosa TN, Santos REB, Soares R, Aikawa NE, Bonfa E (2022) Inactivated SARS-CoV-2 vaccine in primary Sj\u00f6gren\u2019s syndrome: humoral response, safety, and effects on disease activity. Clin Rheumatol 19:1\u201311. https:\/\/doi.org\/10.1007\/s10067-022-06134-x","journal-title":"Clin Rheumatol"},{"issue":"6","key":"5164_CR31","doi-asserted-by":"publisher","first-page":"e382","DOI":"10.1016\/S2665-9913(22)00065-0","volume":"4","author":"CM Connolly","year":"2022","unstructured":"Connolly CM, Chiang TP, Teles M, Frey S, Alejo JL, Massie A, Shah AA, Albayda J, Christopher-Stine L, Werbel WA, Segev DL, Paik JJ (2022) Factors associated with poor antibody response to third-dose SARS-CoV-2 vaccination in patients with rheumatic and musculoskeletal diseases. Lancet Rheumatol 4(6):e382\u2013e384. https:\/\/doi.org\/10.1016\/S2665-9913(22)00065-0","journal-title":"Lancet Rheumatol"},{"key":"5164_CR32","doi-asserted-by":"publisher","DOI":"10.1093\/mr\/roac030","author":"Y Kashiwado","year":"2022","unstructured":"Kashiwado Y, Kimoto Y, Sawabe T, Irino K, Nakano S, Hiura J, Wang Q, Kawano S, Ayano M, Mitoma H, Ono N, Arinobu Y, Niiro H, Hotta T, Kang D, Akashi K, Ohshima S, Takeuchi T, Horiuchi T (2022) Antibody response to SARS-CoV-2 mRNA vaccines in patients with rheumatic diseases in Japan: \u0131nterim analysis of a multicenter cohort study. Mod Rheumatol. https:\/\/doi.org\/10.1093\/mr\/roac030","journal-title":"Mod Rheumatol"},{"issue":"6","key":"5164_CR33","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1136\/annrheumdis-2021-221916","volume":"81","author":"CSR Araujo","year":"2022","unstructured":"Araujo CSR, Medeiros-Ribeiro AC, Saad CGS, Bonfiglioli KR, Domiciano DS, Shimabuco AY, Silva MSR, Yuki EFN, Pasoto SG, Pedrosa T, Kupa LVK, Zou G, Pereira RMR, Silva CA, Aikawa NE, Bonfa E (2022) Two-week methotrexate discontinuation in patients with rheumatoid arthritis vaccinated with inactivated SARS-CoV-2 vaccine: a randomised clinical trial. Ann Rheum Dis 81(6):889\u2013897. https:\/\/doi.org\/10.1136\/annrheumdis-2021-221916","journal-title":"Ann Rheum Dis"},{"key":"5164_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000521343","volume":"10","author":"JM Classen","year":"2021","unstructured":"Classen JM, Muzalyova A, Nagl S, Fleischmann C, Ebigbo A, R\u00f6mmele C, Messmann H, Schnoy E (2021) Antibody response to SARS-CoV-2 vaccination in patients with inflammatory bowel disease- results of a single-center cohort study in a tertiary hospital in Germany. Dig Dis 10:1\u20139. https:\/\/doi.org\/10.1159\/000521343","journal-title":"Dig Dis"},{"issue":"10","key":"5164_CR35","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1136\/annrheumdis-2021-220647","volume":"80","author":"V Furer","year":"2021","unstructured":"Furer V, Eviatar T, Zisman D, Peleg H, Paran D, Levartovsky D, Zisapel M, Elalouf O, Kaufman I, Meidan R, Broyde A, Polachek A, Wollman J, Litinsky I, Meridor K, Nochomovitz H, Silberman A, Rosenberg D, Feld J, Haddad A, Gazzit T, Elias M, Higazi N, Kharouf F, Shefer G, Sharon O, Pel S, Nevo S, Elkayam O (2021) Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study. Ann Rheum Dis 80(10):1330\u20131338. https:\/\/doi.org\/10.1136\/annrheumdis-2021-220647","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"5164_CR36","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1136\/gutjnl-2021-324388","volume":"70","author":"NA Kennedy","year":"2021","unstructured":"Kennedy NA, Goodhand JR, Bewshea C, Nice R, Chee D, Lin S, Chanchlani N, Butterworth J, Cooney R, Croft NM, Hart AL, Irving PM, Kok KB, Lamb CA, Limdi JK, Macdonald J, McGovern DP, Mehta SJ, Murray CD, Patel KV, Pollok RC, Raine T, Russell RK, Selinger CP, Smith PJ, Bowden J, McDonald TJ, Lees CW, Sebastian S, Powell N, Ahmad T, Contributors to the CLARITY IBD Study (2021) Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab. Gut 70(5):865\u2013875. https:\/\/doi.org\/10.1136\/gutjnl-2021-324388 (PMID: 33753421; PMCID: PMC7992387)","journal-title":"Gut"},{"key":"5164_CR37","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1038\/s41591-021-01469-5","volume":"10","author":"AC Medeiros-Ribeiro","year":"2021","unstructured":"Medeiros-Ribeiro AC, Aikawa NE, Saad CGS, Yuki EFN, Pedrosa T, Fusco SRG, Rojo PT, Pereira RMR, Shinjo SK, Andrade DCO, Sampaio-Barros PD, Ribeiro CT, Deveza GBH, Martins VAO, Silva CA, Lopes MH, Duarte AJS, Antonangelo L, Sabino EC, Kallas EG, Pasoto SG, Bonfa E (2021) Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial. Nat Med 10:1744\u20131751. https:\/\/doi.org\/10.1038\/s41591-021-01469-5","journal-title":"Nat Med"},{"issue":"10","key":"5164_CR38","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1111\/j.1440-1746.2005.03903.x","volume":"20","author":"E Erkek","year":"2005","unstructured":"Erkek E, Ayaslioglu E, Erkek AB, Kurtipek GS, Bagci Y (2005) Response to vaccination against hepatitis B in patients with Behcet\u2019s disease. J Gastroenterol Hepatol 20(10):1508\u20131511. https:\/\/doi.org\/10.1111\/j.1440-1746.2005.03903.x (PMID: 16174066)","journal-title":"J Gastroenterol Hepatol"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-022-05164-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00296-022-05164-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-022-05164-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T06:05:55Z","timestamp":1662098755000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00296-022-05164-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,2]]},"references-count":38,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022,10]]}},"alternative-id":["5164"],"URL":"https:\/\/doi.org\/10.1007\/s00296-022-05164-7","relation":{},"ISSN":["1437-160X"],"issn-type":[{"type":"electronic","value":"1437-160X"}],"subject":[],"published":{"date-parts":[[2022,7,2]]},"assertion":[{"value":"1 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ayse Ozdede, Okan Kadir Nohut, Zeynep Atli, Ye\u015fim Tuyji Tok, Sabriye Guner, Erkan Yilmaz, Didar Ucar, Ugur Uygunoglu and Vedat Hamuryudan declare that they have no conflict of interest. Emire Seyahi has received honoraria, consulting or speaker fees from Novartis, Pfizer, AbbVie and Gilead.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of \u0131nterest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}